SLC5A2 and cancer: Therefore, SGLT2 inhibitors should be considered in cancer patients with established HFrEF, as well as those undergoing high-risk cardiotoxic therapies or exhibiting early signs of cardiac dysfunction (e.g., abnormal GLS, rising troponin or NT-proBNP) [63,66].